
-
Cyclerion Therapeutics NasdaqCM:CYCN Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Location: 245 First Street, Riverview II, Cambridge, MA, 02142, United States | Website: https://www.cyclerion.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
5.253M
Cash
3.639M
Avg Qtr Burn
-857.5K
Short % of Float
1.09%
Insider Ownership
32.73%
Institutional Own.
12.22%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zagociguat (CY6463) Details Neurological disorder, Alzheimer's disease, Dementia | Phase 2 Update | |
Zagociguat (CY6463) Details Cognitive Impairment Associated with Schizophrenia | Phase 1b Update | |
Zagociguat (CY6463) Details Rare diseases, Mitochondrial disease, Rare genetic disease | Failed Discontinued | |
Praliciguat (sGC stimulator) Details Heart disease | Failed Discontinued | |
Olinciguat Details Sickle cell disease | Failed Discontinued |